PIA
NVCR icon

Piedmont Investment Advisors’s NovoCure NVCR Stock Holding History

Piedmont Investment Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,248
Closed -$39K – 1859
2018
Q2 		$39K Buy
+1,248
New +$34.7K ﹤0.01% 1380

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Piedmont Investment Advisors's NVCR Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of NovoCure (NVCR) in Q3 2018, closing a stake of 1,248 shares — an estimated $39K sold.

Piedmont Investment Advisors first reported a position in NVCR in Q2 2018 and held it in 1 quarter. The position peaked at $39K in Q2 2018. 176 funds tracked by Wall St. Rank hold NVCR as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining NovoCure position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 1,248 NovoCure shares in Q3 2018, an estimated $39K.
  • Piedmont Investment Advisors first reported a position in NovoCure in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's NovoCure position peaked at $39K in Q2 2018.
  • 176 funds tracked by Wall St. Rank held NovoCure as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.